Similar articles for PMID: 21220436

Year	Number of Results
1919	1
1983	1
1996	1
1999	1
2000	1
2001	1
2002	2
2003	3
2004	1
2005	3
2006	4
2008	3
2009	1
2010	9
2011	4
2012	5
2013	8
2014	6
2015	7
2016	6
2017	6
2018	11
2019	7
2020	12
2021	11
2022	7
2023	1

1

Adverse events associated with treatment of latent tuberculosis in the general population.

Smith BM, Schwartzman K, Bartlett G, Menzies D. Smith BM, et al. CMAJ. 2011 Feb 22;183(3):E173-9. doi: 10.1503/cmaj.091824. Epub 2011 Jan 10. CMAJ. 2011. PMID: 21220436 Free PMC article.

2

Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.

Ronald LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, Benedetti A, Boivin JF, Menzies D. Ronald LA, et al. Eur Respir J. 2020 Mar 20;55(3):1902048. doi: 10.1183/13993003.02048-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31980498 Free article.

3

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K. Menzies D, et al. Ann Intern Med. 2008 Nov 18;149(10):689-97. doi: 10.7326/0003-4819-149-10-200811180-00003. Ann Intern Med. 2008. PMID: 19017587 Clinical Trial.

4

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.

Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D. Campbell JR, et al. Lancet Infect Dis. 2020 Mar;20(3):318-329. doi: 10.1016/S1473-3099(19)30575-4. Epub 2019 Dec 19. Lancet Infect Dis. 2020. PMID: 31866327

5

A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.

Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, Skidmore B, Alvarez GG. Pease C, et al. Pharmacoepidemiol Drug Saf. 2018 Jun;27(6):557-566. doi: 10.1002/pds.4423. Epub 2018 Mar 23. Pharmacoepidemiol Drug Saf. 2018. PMID: 29573031

6

Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM. Walker RE, et al. Ann Pharmacother. 2020 May;54(5):457-463. doi: 10.1177/1060028019888855. Epub 2019 Nov 15. Ann Pharmacother. 2020. PMID: 31729245

7

Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.

Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Belknap R, et al. Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. Ann Intern Med. 2017. PMID: 29114781 Free PMC article. Clinical Trial.

8

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Jasmer RM, et al. Ann Intern Med. 2002 Oct 15;137(8):640-7. doi: 10.7326/0003-4819-137-8-200210150-00007. Ann Intern Med. 2002. PMID: 12379063 Clinical Trial.

9

Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.

White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM. White MC, et al. J Correct Health Care. 2012 Apr;18(2):131-42. doi: 10.1177/1078345811435973. Epub 2012 Mar 14. J Correct Health Care. 2012. PMID: 22419641 Free PMC article. Clinical Trial.

10

Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.

Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME; Tuberculosis Trials Consortium. Sterling TR, et al. Clin Infect Dis. 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22. Clin Infect Dis. 2015. PMID: 25904367 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed